← All trials
NCT05483491
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 26, 2022
- Primary completion
- Sep 1, 2023
- Completion date
- Dec 31, 2028
- First posted
- Aug 2, 2022
- Last posted
- Sep 29, 2022
- Enrollment
- 42
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rutgers UniversityLead sponsor
- National Cancer Institute (NCI)Collaborator
- Rutgers UniversityCollaborator
- Rutgers UniversityOverall official - principal investigator
- Rutgers UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.